NCT00556699View on ClinicalTrials.gov

A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

rituximab

Escalating intravenous repeating dose

DRUG

SGN-40

Escalating intravenous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

Genentech, Inc.

INDUSTRY